Cortechs.ai | Cortechs.ai announces Health Canada/Santé Canada license for NeuroQuant®

Cortechs.ai announces Health Canada/Santé Canada license for NeuroQuant®

Cortechs.ai expands market reach into Canada for NeuroQuant, the leading volumetric brain imaging solution for MRIs.

(SAN DIEGO) Feb. 2, 2016 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce that it has received Health Canada/Santé Canada Medical Device License for marketing and distribution of NeuroQuant® in Canada. Already FDA cleared and CE marked, NeuroQuant is used throughout the world by physicians in hundreds of reputable clinics and hospitals to help in their assessment of neurodegeneration.

Fully automated, NeuroQuant provides neurologists, radiologists, and clinical researchers with an accurate and convenient tool to quantify the volumes of specific brain structures in order to better assess neurological conditions such as Alzheimer’s disease, brain trauma, multiple sclerosis, epilepsy and brain development.

“The Heath Canada/Santé Canada Medical Device License is a testament to our commitment to quality, safety and performance and now allows customers in Canada to start using NeuroQuant in their clinical practice,” commented Guri Stark, CEO of Cortechs.ai. “We are excited to introduce our innovative brain imaging solution to Canadian hospitals, clinics and universities and expand access to proven and reliable quantitative volumetric analysis of neurological conditions via MR imaging.”

About Cortechs.ai

Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of MRI images of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit cortechs.ai for further information.

###

Contact: Travis Foegler
Phone: +1 (619) 450-9094
Email: Tfoegler@cortechs.ai

More Resources

07/09/2026

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai’s health system network

07/08/2026

The Hidden Tax on Every Head CT You Read

Why automated, consistent alignment, and the reformats it makes possible, may be the most overlooked upgrade in neuroimaging.

06/23/2026

Helping Our Clients Share Their Success Stories

Learn how Cortechs helps clients share clinical achievements, workflow improvements, and innovation through case studies, testimonials, webinars, and more.

06/15/2026

Alzheimer’s Awareness Month: Bringing Clarity to the Alzheimer’s Care Continuum Through Quantitative Imaging

Explore how quantitative imaging is helping clinicians assess, diagnose, and monitor Alzheimer’s disease and related dementias with greater clarity.

06/08/2026

Cortechs.ai and TAC Center Celebrate One Year of Advancing Neuroimaging Innovation in Peru

TAC Centers Peru is celebrating one year of integrating the NeuroQuant® suite into clinical practice.

06/04/2026

SNMMI 2026: Advancing the Future of Quantitative PET in Dementia Imaging

At SNMMI 2026, Cortechs.ai showcased NeuroQuant® PET and the growing role of quantitative PET imaging in dementia care.
Scroll to Top